scholarly journals Secondary malignancies after radiation therapy in prostate cancer survivors: a propensity-score matched competing-risk analysis

2020 ◽  
Vol 9 (4) ◽  
pp. 2847-2854
Author(s):  
Lei Yu ◽  
Jun Xu ◽  
Zhen Fan ◽  
Wenxian Li ◽  
Hongqiang Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Propensity Score ◽  
Risk Analysis ◽  
Cancer Survivors ◽  
Competing Risk ◽  
Secondary Malignancies ◽  
Competing Risk Analysis ◽  
Prostate Cancer Survivors

Risk of second primary malignancies associated with radiotherapy in prostate cancer patients: competing risk analysis

2022 ◽  
Author(s):  
Yijun Wu ◽  
Yunlong Li ◽  
Chang Han ◽  
Yuming Chong ◽  
Kai Kang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Analysis ◽  
Cancer Survivors ◽  
Cancer Patients ◽  
Competing Risk ◽  
Second Primary ◽  
Competing Risk Analysis ◽  
Matching Method ◽  
Prostate Cancer Survivors ◽  
Second Primary Malignancies

Background: The effect of radiotherapy (RT) for second primary malignancies (SPMs) among prostate cancer survivors is controversial. Methods: Applying logistic regression, competing risk analysis and propensity score matching method, this study analyzed clinical data from the Surveillance, Epidemiology, and End Results program to compare the risk for SPMs between patients receiving RT and non-RT. Results: In this study, prostate cancer patients treated with RT developed more SPMs in the anus, bladder, rectum, liver, lung and bronchus and lymphoma than non-RT groups. Conclusion: More intensive surveillance should be adopted for these cancers among prostate cancer survivors.

Competing risk analysis of mortality in prostate cancer treated with radical prostatectomy

2017 ◽  
Vol 41 (1) ◽  
pp. 11-22
Author(s):  
J.L. Ruiz-Cerdá ◽  
A. Soto-Poveda ◽  
S. Luján-Marco ◽  
A. Loras-Monfort ◽  
M. Trassierra-Villa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Risk Analysis ◽  
Competing Risk ◽  
Competing Risk Analysis

Competing Risk Analysis for Causes of Death in Men With High-Risk Prostate Cancer

2012 ◽  
Vol 84 (3) ◽  
pp. S414
Author(s):  
G.K. Hunter ◽  
C.A. Reddy ◽  
K.L. Stephans ◽  
J.P. Ciezki ◽  
A.J. Stephenson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Risk Analysis ◽  
Causes Of Death ◽  
Competing Risk ◽  
Competing Risk Analysis ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

scholarly journals Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Chi-Jung Tai ◽  
Yi-Hsin Yang ◽  
Tzyy-Guey Tseng ◽  
Fang-Rong Chang ◽  
Hui-Chun Wang
Keyword(s):  
Cohort Study ◽  
Propensity Score ◽  
Risk Analysis ◽  
Cancer Prevention ◽  
Cancer Incidence ◽  
Competing Risk ◽  
Research Database ◽  
Competing Risk Analysis ◽  
Β Blocker

Background: Previous studies neglected death as a critical competing risk while estimating the cancer risk for digoxin users. Therefore, the current study aims to assess the effectiveness of digoxin on cancer prevention by competing risk analysis.Methods: We performed a population-based retrospective cohort study using the Taiwan National Health Insurance Research database between 1998 and 2010. After one-to-one propensity score-matching from 36,160 patients with defined criteria, we enrolled 758 patients both in digoxin and β-blocker group for further analysis.Results: The results showed that the digoxin group had higher all-cause mortality than the β-blocker group in the 4- year (10.4 vs. 4.9%) and 8 years (13.6 vs. 7.0%) follow-up. The subdistribution HR of cancer incidence in the digoxin group compared to the β-blocker group was 1.99 (95% confidence interval [CI]: 1.22–3.01) and 1.46 (95% CI: 1.01–2.15) in the 4 years and 8 years follow-up, respectively.Conclusions: The result of our study showed the usage of digoxin has no benefit in cancer prevention compared with β-blocker. The possibility of β-blocker as a new drug candidate for cancer prevention needs further clinical evaluation. The current study also emphasized the necessity of competing risk analysis applying to similar clinical researches.

Sign in / Sign up

Export Citation Format

Share Document